Multi-layered functional genomics prioritizes candidate effectors and regulatory mechanisms of ankylosing spondylitis - Scorecard - MDSpire

Multi-layered functional genomics prioritizes candidate effectors and regulatory mechanisms of ankylosing spondylitis

  • By

  • Fanyu Meng

  • Ling Chen

  • Meng Li

  • Qingqing Zhang

  • Peiying Wang

  • Ruifeng Lin

  • Jiani Liu

  • Zhao Yuan

  • Kexin Chen

  • Zhaoxia Li

  • Yetong Xie

  • Abuduwahapu Aierken

  • Furkat Yalkun

  • Chulan Li

  • Yuan Ma

  • Jianhui Chen

  • Ziwen Xu

  • Fei Zhong

  • June 1, 2026

  • 0 min

Share

Clinical Scorecard: Prioritization of Candidate Effectors and Regulatory Pathways in Ankylosing Spondylitis Through Multi-layered Functional Genomics

At a Glance

CategoryDetail
ConditionAnkylosing Spondylitis (AS)
Key MechanismsInvolvement of immune-related genes and regulatory pathways, particularly in the MHC region and associated with T helper 17 cell differentiation.
Target PopulationIndividuals with Ankylosing Spondylitis, primarily of European ancestry.
Care SettingResearch and clinical genetics.

Key Highlights

  • Identified 30 genome-wide significant loci with 26,178 significant variants.
  • Prioritized 64 causal-candidate genes with gene expression explaining 19.5% of AS heritability.
  • Demonstrated positive genetic correlations with inflammatory bowel disease and psoriasis.
  • Utilized advanced computational models for gene perturbation and variant effect prediction.

Guideline-Based Recommendations

Diagnosis

  • Utilize genetic testing for HLA-B*27 and other identified loci in suspected AS cases.

Management

  • Consider immunomodulatory therapies targeting identified pathways.

Monitoring & Follow-up

  • Regular assessment of disease progression and response to therapies.

Risks

  • Increased risk of associated conditions such as inflammatory bowel disease and psoriasis.

Patient & Prescribing Data

Patients diagnosed with Ankylosing Spondylitis, particularly those with genetic predispositions.

Focus on therapies that target immune pathways implicated in AS pathogenesis.

Clinical Best Practices

  • Integrate genetic and genomic data into clinical decision-making.
  • Employ multi-omics approaches for comprehensive understanding of AS.

Related Resources & Content

Original Source(s)

Related Content